Valeant selling 4 assets for $2.1B in cash grab: 4 takeaways

To combat its $30 billion debt, Lovell, Canada-based Valeant Pharmaceuticals is selling its Dendreon cancer business and three of its skincare brands for $2.12 billion.

Advertisement

Here’s what you should know.

1. Valeant is selling its Dendreon immunotherapy prostate cancer business to China-based Sanpower Group for $819.9 million.

2. Additionally, Valeant is selling its CeraVe, AMBI Skincare and AcneFree skincare brands to Île-de-France-based L’Oreal for $1.3 billion.

The three product lines yielded an annual revenue of $168 million for Valeant.

3. Valeant expects to close on both transactions in early 2017.

4. The sales’ proceeds will pay back some of Valeant’s term loan debt.

More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Bitman Stewart of Digestive Care
Integrated Endoscopy seeks $4.4M for executive compensation: 3 key notes
Hallmark Health Medical Associates names gastroenterologist Dr. Michael Newman president: 3 key notes

Advertisement

Next Up in GI & Endoscopy

  • The MUSC Shawn Jenkins Children’s Hospital in Charleston, S.C., has launched the MUSC Advanced Pediatric Endoscopy Program and Pancreas Center. …

  • For GI clinics and ASCs, accurate coding and documentation are critical to protecting reimbursement, reducing denials and withstanding payer audits. …

Advertisement

Comments are closed.